Skip to main content

Advertisement

SpringerLink
Log in

Hemiplegic Migraine

  • Published:
Current Neurology and Neuroscience Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

In this article, we review recent updates to the epidemiology, diagnostic testing, genetics, pathophysiology, and management of hemiplegic migraine.

Recent Findings

While three genes have been historically associated with hemiplegic migraine, recent studies suggest two additional genes may also be implicated including PPRT2 and SLC1A3.

Summary

Hemiplegic migraine is a severe subset of migraine with aura with symptoms including reversible hemiparesis in addition to other aura symptoms such as visual, sensory, or speech. The exact pathophysiology of hemiplegic migraine is not clear, but it is thought that this phenomenon is due to neuronal and glial depolarization causing cortical spreading depression. Due to the severity of presentation as well as the numerous mimickers, it is important to know a comprehensive differential and work-up. Given the low prevalence of the disease, most studies regarding treatment are limited to case studies. There is still an important need for further and larger studies regarding management of these cases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Olesen J. Headache classification committee of the international headache society (IHS) the international classification of headache disorders. Cephalalgia. 2018;38(1):1–211.

    Article  Google Scholar 

  2. Thomsen LL, Eriksen MK, Romer SF, Andersen I, Ostergaard E, Keiding N, Olesen J, Russell MB. An epidemiological survey of hemiplegic migraine. Cephalalgia. 2002;22(5):361–75.

    Article  Google Scholar 

  3. Moore BA, Hale WJ, Nabity PS, Koehn TR, McGeary D, Peterson AL. A retrospective, epidemiological review of hemiplegic migraines in a military population. Mil Med. 2019;184(11-12):781–7.

    Article  PubMed  Google Scholar 

  4. • Di Stefano V, Rispoli MG, Pellegrino N, Graziosi A, Rotondo E, Napoli C, Pietrobon D, Brighina F, Parisi P. Diagnostic and therapeutic aspects of hemiplegic migraine. J Neurol Neurosurg Psychiatry. 2020;91(7):764–71. Detailed review of differential diagnosis and studied treatment options.

    Article  PubMed  Google Scholar 

  5. Thomsen LL, Ostergaard E, Olesen J, Russell MB. Evidence for a separate type of migraine with aura: sporadic hemiplegic migraine. Neurology. 2003;60(4):595–601.

    Article  PubMed  Google Scholar 

  6. Vincent M, Hadjikhani N. The cerebellum and migraine. Headache. 2007;47(6):820–33.

  7. Trahan EM, Mercado JM. Familial hemiplegic migraines and baseline neuropsychological testing: a case report. Headache. 2019;59(6):917–23.

    Article  PubMed  Google Scholar 

  8. Sprouse Blum AS, Couperus CJ, Rosen BJ, Haskin-Leahy LF, Shapiro RE. Familial “diplegic” migraine–description of a family with a novel CACNA1A mutation. Headache. 2020;60(3):600–6.

    Article  PubMed  Google Scholar 

  9. Antonaci F, Ravaglia S, Grieco GS, Gagliardi S, Cereda C, Costa A. Familial hemiplegic migraine type 2 due to a novel missense mutation in ATP1A2. J Headache Pain. 2021;22(1):1–6.

    Article  Google Scholar 

  10. Tang W, Zhang M, Qiu E, Kong S, Li Y, Liu H, Dong Z, Yu S. A Chinese family with familial hemiplegic migraine type 2 due to a novel missense mutation in ATP1A2. Cephalalgia. 2019;39(11):1382–95.

    Article  PubMed  Google Scholar 

  11. Maksemous N, Smith RA, Sutherland HG, Maher BH, Ibrahim O, Nicholson GA, Carpenter EP, Lea RA, Cader MZ, Griffiths LR. Targeted next generation sequencing identifies a genetic spectrum of DNA variants in patients with hemiplegic migraine. Cephalalgia Rep. 2019;11(2):2515816319881630.

    Google Scholar 

  12. Bertelli S, Barbieri R, Pusch M, Gavazzo P. Gain of function of sporadic/familial hemiplegic migraine-causing SCN1A mutations: use of an optimized cDNA. Cephalalgia. 2019;39(4):477–88.

    Article  PubMed  Google Scholar 

  13. •• Riant F, Roos C, Roubertie A, Barbance C, Hadjadj J, Auvin S, Baille G, Beltramone M, Boulanger C, Cahn A, Cata F. Hemiplegic migraine associated with PRRT2 variations: a clinical and genetic study. Neurology. 2022;98(1):e51–61. Study related to newly identified gene variant, PRRT2.

    Article  PubMed  Google Scholar 

  14. •• Paucar M, Granberg T, Lagerstedt-Robinson K, Waldenlind E, Petersson S, Nordin L, Svenningsson P. SLC1A3 variant associated with hemiplegic migraine and acetazolamide-responsive MRS changes. Neurology. Genetics. 2020;6(4). https://doi.org/10.1212/NXG.0000000000000474Case report describing new SCL1A3 variant.

  15. Kumar A, Samanta D, Emmady PD, Arora R. Hemiplegic migraine. 2018.

  16. Thomsen LL, Olesen J. Sporadic hemiplegic migraine. Cephalalgia. 2004;24(12):1016–23.

    Article  CAS  PubMed  Google Scholar 

  17. Magni G, Boccazzi M, Bodini A, Abbracchio MP, van den Maagdenberg AM, Ceruti S. Basal astrocyte and microglia activation in the central nervous system of familial hemiplegic migraine type I mice. Cephalalgia. 2019;39(14):1809–17.

    Article  PubMed  Google Scholar 

  18. Dichgans M, Herzog J, Freilinger T, Wilke M, Auer DP. 1H-MRS alterations in the cerebellum of patients with familial hemiplegic migraine type 1. Neurology. 2005;64(4):608–13.

    Article  CAS  PubMed  Google Scholar 

  19. Toldo I, Cecchin D, Sartori S, Calderone M, Mardari R, Cattelan F, Laverda AM, Drigo P, Battistella PA. Multimodal neuroimaging in a child with sporadic hemiplegic migraine: a contribution to understanding pathogenesis. Cephalalgia. 2011;31(6):751–6.

    Article  PubMed  Google Scholar 

  20. Wang R, Nie X, Xu S, Zhang M, Dong Z, Yu S. Interrelated pathogenesis? Neuronal intranuclear inclusion disease combining with hemiplegic migraine. Headache. 2020;60(2):382–95.

    Article  PubMed  Google Scholar 

  21. Gastaut JL, Yermenos E, Bonnefoy M, Cros D. Familial hemiplegic migraine: EEG and CT scan study of two cases. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society. 1981;10(4):392–395. https://doi.org/10.1002/ana.410100414

  22. Russell MB, Ducros A. Sporadic and familial hemiplegic migraine: pathophysiological mechanisms, clinical characteristics, diagnosis, and management. Lancet Neurol. 2011;10(5):457–70.

    Article  PubMed  Google Scholar 

  23. Pellerin A, Marois C, Mezouar N, Mokhtari K, Leclercq D, Law-Ye B. Neuronal injuries evidenced by transient cortical magnetic resonance enhancement in hemiplegic migraine: a case report. Cephalalgia. 2019;39(2):323–5.

    Article  PubMed  Google Scholar 

  24. Jen JC . Familial Hemiplegic Migraine. GeneReviews® [Internet] 2021. https://www.ncbi.nlm.nih.gov/books/NBK1388/

  25. Artto V, Nissilä M, Wessman M, Palotie A, Färkkilä M, Kallela M. Treatment of hemiplegic migraine with triptans. Eur J Neurol. 2007;14(9):1053–6.

    Article  CAS  PubMed  Google Scholar 

  26. Mathew PG, Krel R, Buddhdev B, Ansari H, Joshi SG, Spinner WD, Klein BC. A retrospective analysis of triptan and dhe use for basilar and hemiplegic migraine. Headache. 2016;56(5):841–8.

    Article  PubMed  Google Scholar 

  27. Mathew PG, Klein BC. Getting to the heart of the matter: migraine, triptans, DHE, ditans, CGRP antibodies, first/second-generation gepants, and cardiovascular risk. Headache. 2019;59(8):1421–6.

    Article  PubMed  Google Scholar 

  28. Chen TY, Garza I, Dodick DW, Robertson CE. The effect of OnabotulinumtoxinA on aura frequency and severity in patients with hemiplegic migraine: case series of 11 patients. Headache. 2018;58(7):973–85.

    Article  PubMed  Google Scholar 

  29. Dannenberg F, Prager C, Schmidt F, Tietze A, Bittigau P, Kaindl AM. Intravenous nimodipine treatment for severe episode of ATP1A2 hemiplegic migraine. Pediatr Neurol. 2020;1(112):71–2.

    Article  Google Scholar 

  30. Hansen JM, Thomsen LL, Olesen J, Ashina M. Calcitonin gene-related peptide does not cause migraine attacks in patients with familial hemiplegic migraine. Headache. 2011;51(4):544–53.

    Article  PubMed  Google Scholar 

  31. Hansen JM, Thomsen LL, Olesen J, Ashina M. Calcitonin gene–related peptide does not cause the familial hemiplegic migraine phenotype. Neurology. 2008;71(11):841–7.

    Article  CAS  PubMed  Google Scholar 

  32. Kaube H, Herzog J, Käufer T, Dichgans M, Diener HC. Aura in some patients with familial hemiplegic migraine can be stopped by intranasal ketamine. Neurology. 2000;55(1):139–41.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, MedStar Georgetown University Hospital, 3800 Reservoir Road NW, 7PHC, Washington, DC, 20007, USA

    Arathi Nandyala, Tulsi Shah & Jessica Ailani

Authors
  1. Arathi Nandyala
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tulsi Shah
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jessica Ailani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Arathi Nandyala.

Ethics declarations

Conflict of Interest

Arathi Nandyala: none.

Tulsi Shah: none.

Jessica Ailani:

-Stock/stock options: CtrlM (2022)

-Editorial Boards/Steering Committee: Medscape, NeurologyLive, Current Pain and Headache (Editor, Unusual Headache Syndromes), SELF magazine (medical editor)

-Leadership or fiduciary role in other board society, committee or advocacy group: American Headache Society (unpaid)

-Participation on a Data Safety Monitoring Board or Advisory Board: Aeon (migraine) and Gore (migraine)

-Consulting fees: Abbvie, Amgen, Axsome, Biohaven, BioDeliveryScientificInternational (2022), Eli-Lilly, GlaxoSmithKline, Lundbeck, Linpharma, Impel, Miravio, Pfizer, Neurolief, Neso, Satsuma, Theranica, Teva

-Grants or contracts from any entity: Clinical Trials (Grant to institution)—Abbvie (2021), Biohaven (2021), Eli-Lilly (2021), Satsuma (2022), Zosano (2021)

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nandyala, A., Shah, T. & Ailani, J. Hemiplegic Migraine. Curr Neurol Neurosci Rep 23, 381–387 (2023). https://doi.org/10.1007/s11910-023-01277-z

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11910-023-01277-z

Keywords

Search

Navigation